Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses tipifarnib for the treatment of older, untreated patients with AML.
Harry Erba, MD, PhD
Harry Erba, MD, PhD, is a professor of medicine at Duke Cancer Institute, chair of the SWOG Leukemia Committee and co-chair of the myeloMATCH Senior Science Council.
Articles by Harry Erba, MD, PhD